<DOC>
	<DOCNO>NCT01655511</DOCNO>
	<brief_summary>This study healthy male female volunteer investigate safety tolerability three increase oral dos tafamidis</brief_summary>
	<brief_title>Safety And Pharmacokinetic Assessment Of Orally Administered Tafamidis In Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Cardiomyopathies</mesh_term>
	<criteria>Healthy , males female , 21 55 year old . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Condition affect drug absorption . Blood pressure ECG abnormality . Recent treatment investigational , prescription , nonprescription drug</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Pharmacokinetic</keyword>
	<keyword>pharmacodynamic</keyword>
</DOC>